Methotrexate As a Safe Immunosuppressive Agent During the COVID-19 Pandemic

Overview

Journal Int Immunopharmacol

Specialties Allergy & Immunology
Pharmacology

Date 2021 Nov 3

PMID 34731780

Citations 10

Authors

Zakiye Ganjei

Hoorvash Faraji Dana

Sepehr Ebrahimi-Dehkordi

Fereshte Alidoust

Kiumars Bahmani

Affiliations

Soon will be listed here.

Abstract

Background: During the ongoing COVID-19 pandemic, immunocompromised patients are at a higher risk of severe infection, since the immune system has an important role in defeating this disease. This study compares the severity of COVID-19 in patients taking methotrexate with the severity of their family members' illness as patients with normal immune system function.

Methods: A total of 35 participants, including 14 patients taking methotrexate and 21 patients with normal immune function, entered this study, and the indicators of COVID-19 severity were compared between these two groups.

Results: The case group, who were on methotrexate therapy, had significantly less severe COVID-19 based on their symptoms, including fever (p = 0.000) and cough and dyspnea (p = 0.01) as well as in terms of COVID-19 severity indicators such as pulmonary involvement (p = 0.001), ferritin level (p = 0.001), white blood cell count (p = 0.008) and CRP level (p = 0.006), compared to the control group. There was a significant correlation between taking methotrexate and lower severity in COVID-19 disease.

Conclusion: The present findings demonstrated that methotrexate does not predispose patients to severe COVID-19; on the contrary, patients taking methotrexate may experience a milder disease, possibly due to their reduced severe inflammatory reactions as a result of inhibited TNFα, lowered IL6, and increased T regulatory cells. According to these findings, methotrexate appears to be a suitable treatment option for patients who need immunosuppressive medications during the COVID-19 pandemic.

Citing Articles

New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse.

Wang K, Li J, Guo K, Zhang X BMC Ophthalmol. 2024; 24(1):196.

PMID: 38671401 PMC: 11046742. DOI: 10.1186/s12886-024-03458-x.

Bioinformatics and system biology approach to identify the influences among COVID-19, influenza, and HIV on the regulation of gene expression.

Zhang Z, Jin H, Zhang X, Bai M, Zheng K, Tian J Front Immunol. 2024; 15:1369311.

PMID: 38601162 PMC: 11004287. DOI: 10.3389/fimmu.2024.1369311.

Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.

Chebbi P, Shobha V, Rao V, Haridas V, Janardana R, Pinto B BMC Rheumatol. 2023; 7(1):22.

PMID: 37496101 PMC: 10369741. DOI: 10.1186/s41927-023-00345-8.

The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.

Maynard N, Armstrong A Curr Dermatol Rep. 2023; 12(2):45-55.

PMID: 37304177 PMC: 10068706. DOI: 10.1007/s13671-023-00385-w.

DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action.

Iaconis D, Caccuri F, Manelfi C, Talarico C, Bugatti A, Filippini F Viruses. 2023; 15(5).

PMID: 37243214 PMC: 10221469. DOI: 10.3390/v15051128.

References

Novaes G, Mello S, Laurindo I, Cossermelli W . Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. J Rheumatol. 1996; 23(12):2092-7. View

Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z . Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020; 6(1):83. PMC: 7653987. DOI: 10.1038/s41421-020-00231-4. View

Englund J, Feuchtinger T, Ljungman P . Viral infections in immunocompromised patients. Biol Blood Marrow Transplant. 2011; 17(1 Suppl):S2-5. PMC: 3030455. DOI: 10.1016/j.bbmt.2010.11.008. View

Bedoui Y, Guillot X, Selambarom J, Guiraud P, Giry C, Jaffar-Bandjee M . Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019; 20(20). PMC: 6834162. DOI: 10.3390/ijms20205023. View

Darif D, Hammi I, Kihel A, Saik I, Guessous F, Akarid K . The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?. Microb Pathog. 2021; 153:104799. PMC: 7889464. DOI: 10.1016/j.micpath.2021.104799. View

Manuel O, Estabrook M . RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13511. PMC: 7162209. DOI: 10.1111/ctr.13511. View

Peiris J, Lai S, Poon L, Guan Y, Yam L, Lim W . Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361(9366):1319-25. PMC: 7112372. DOI: 10.1016/s0140-6736(03)13077-2. View

Becker C, Barbulescu K, Hildner K, Meyer zum Buschenfelde K, Neurath M . Activation and methotrexate-mediated suppression of the TNF alpha promoter in T cells and macrophages. Ann N Y Acad Sci. 1999; 859:311-4. DOI: 10.1111/j.1749-6632.1998.tb11153.x. View

Jones S, Jenkins B . Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018; 18(12):773-789. DOI: 10.1038/s41577-018-0066-7. View

10.

Chan E, Cronstein B . Methotrexate--how does it really work?. Nat Rev Rheumatol. 2010; 6(3):175-8. DOI: 10.1038/nrrheum.2010.5. View

11.

Swain S, McKinstry K, Strutt T . Expanding roles for CD4⁺ T cells in immunity to viruses. Nat Rev Immunol. 2012; 12(2):136-48. PMC: 3764486. DOI: 10.1038/nri3152. View

12.

Hyoun S, Obican S, Scialli A . Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012; 94(4):187-207. DOI: 10.1002/bdra.23003. View

13.

Tanaka T, Narazaki M, Kishimoto T . IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10):a016295. PMC: 4176007. DOI: 10.1101/cshperspect.a016295. View

14.

Johnston A, Gudjonsson J, Sigmundsdottir H, Ludviksson B, Valdimarsson H . The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114(2):154-63. DOI: 10.1016/j.clim.2004.09.001. View

15.

Fajgenbaum D, June C . Cytokine Storm. N Engl J Med. 2020; 383(23):2255-2273. PMC: 7727315. DOI: 10.1056/NEJMra2026131. View

16.

Vargas-Vargas M, Cortes-Rojo C . Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020; 44:e72. PMC: 7286435. DOI: 10.26633/RPSP.2020.72. View

17.

Asilian A, Fatemi F, Ganjei Z, Siadat A, Mohaghegh F, Siavash M . Oral Pulse Betamethasone, Methotrexate, and Combination Therapy to Treat Severe Alopecia Areata: A Randomized, Double-blind, Placebo-controlled, Clinical Trial. Iran J Pharm Res. 2021; 20(1):267-273. PMC: 8170764. DOI: 10.22037/ijpr.2020.113868.14536. View

18.

Li Y, Jiang L, Zhang S, Yin L, Ma L, He D . Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int. 2011; 32(8):2415-22. DOI: 10.1007/s00296-011-1867-1. View

19.

Caruso A, Caccuri F, Bugatti A, Zani A, Vanoni M, Bonfanti P . Methotrexate inhibits SARS-CoV-2 virus replication "in vitro". J Med Virol. 2020; 93(3):1780-1785. PMC: 7891346. DOI: 10.1002/jmv.26512. View

20.

Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S . Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020; 20(7):1859-1863. PMC: 7228349. DOI: 10.1111/ajt.15869. View